Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2

<p class="MsoNormal">Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics: </p> <ul> <li class="MsoNormal">Introduction: Oral Selective Estrogen Receptor Degraders (SERDs) for the General Medical Oncologist (0:00)</li> <li>SERD Monotherapy (13:34)</li> <li>SERD and CDK Inhibitor Combination — The EMBER-3 Study (35:58)</li> <li>SERDs for "Molecular Progression" — The SERENA-6 Study (41:25)</li> </ul> <p class="MsoNormal"><a href= "http://m.researchtopractice.com/OralSERDSmBC2025/2/Video">CME information and select publications</a></p>